Documente Academic
Documente Profesional
Documente Cultură
LIST OF CONTENTS
1 Form -I 1-12
2 List of Products 13
11 Spent Solvents 64
ENCLOSURES
APPENDIX-I
FORM -1
I) Basic information
II) Activity
1. Construction, operation or decommissioning of the Project involving actions,
which will cause physical changes in the locality (topography, land use,
changes in water bodies, etc.)
S. No Information/Checklist Yes/No Details thereof(with approximate
confirmation quantities/rates, wherever
possible)with source of information
data
1.1 Permanent or temporary No It is expansion of the existing plant, No
change in land use, land change in land use, land cover or
cover or topography including topography.
increase in intensity of land
use (with respect to local land
use plan)
1.2 Clearance of existing land, No There will be no clearance of existing
vegetation and buildings? land, vegetation or building.
1.3 Creation of new land uses? No No creation of land use.
1.4 Pre-construction No NA
investigations e.g. bore
houses, soil testing?
1.5 Construction works? No Site paln Enclosed
1.16 Facilities for long term No No housing facilities will be provided for
housing of operational operational workers. Most of the workers
workers? are locals and nearby villages.
1.17 New road, rail or sea traffic No Not envisaged.
during construction or
operation?
1.18 New road, rail, air, waterborne No Not envisaged.
or other transport
infrastructure including new or
altered routes and stations,
ports, airports etc?
1.19 Closure or diversion of No Not envisaged.
existing transport routes or
infrastructure leading to
changes in traffic
movements?
1.20 New or diverted transmission No Not envisaged.
lines or pipelines?
1.21 Impoundment, damming, No No
culverting, realignment or other
changes to the hydrology of
watercourses or aquifers?
1.22 Stream crossings? No There is no stream passing through the
site.
1.23 Abstraction or transfers of Yes Water requirement will be met from the
water from ground or surface Bore well water.
waters?
1.24 Changes in water bodies or No There will not be any changes in water
the land surface affecting bodies or the land surface affecting
drainage or run-off? drainage or run-off.
1.25 Transport of personnel or No NA
materials for construction,
operation or
decommissioning?
1.26 Long-term dismantling or No No dismantling or decommissioning or
decommissioning or restoration works
restoration works?
1.27 Ongoing activity during No NA
decommissioning which could
have an impact on the
environment
1.28 Influx of people to an area in Yes Workers /Employees will be increased
either temporarily or and the working hours are in shifts /
permanently? general.
1.29 Introduction of alien species? No No Introduction of alien species
1.30 Loss of native species or No No Loss of native species or genetic
genetic diversity? diversity
1.31 Any other actions? No __
3.3 Affect the welfare of people No Not applicable .it is only capacity load
e.g. by changing living enhancement.
conditions?
3.4 Vulnerable groups of people No None
who could be affected by the
project e.g. hospital patients,
children, the elderly etc.,
3.5 Any other causes No Nil
4.11 Other solid wastes No Details of other solid waste are given.
7. Risks of contamination of land or water from releases of pollutants into the ground or
into sewers, surface waters, groundwater, coastal waters or the sea:
7.2 From discharge of sewage Yes 12.92 KLD Domestic sewage will be sent
or other effluents to water to soak pit. Process effluent will be
or the land (expected mode treated and evaporated and recycled
and place of discharge) within the plant.
7.3 By deposition of pollutants Yes Possibility of deposition of pollutants
emitted to air into the land emitted to air into the land / water can’t be
or into water ruled out and the precautions taken by
the industries to control such emissions
by adopting the suitable controlling
equipment will be provided such as Bag
filters ,Scrubbers etc.
Prepared by Rightsource Industrial Solutions Pvt Ltd. 8
M/s. Syn- Finechem Laboratories Pvt. Ltd.
8. Risk of accidents during construction or operation of the Project, which could affect
human health or the environment
* Supporting infrastructure
(roads, power supply, waste
or waste water treatment,
etc.)
LIST OF PRODUCTS
1. BOSENTAN
2. DAPAGLIFLOZIN PROPANEDIOL
3. PONATINIB
4. POSACONAZOLE
5. VIDAGLIPTIN
1. BOSENTAN
Process Description
Stage-1
Stage-2
Stage-3
BOSENTAN
Route of Synthesis
Stage-1
NH
HCl
N CN N
NH2
N N
Methanol
NH4Cl
+
Sodium methoxide Pyrimidine-2-carboxamidine
Pyrimidine-2 Ammonium Chloride
Hydrochloride
-carbonitrile 53.49
C5H3N3 C5H7ClN4
105.10 158.59
Stage-2
NH OCH3 OCH3
HCl O
N
NH2 O
N Methanol
+ O OCH3 + NaOCH3
158.59 254.24
OH OCH3
O
N
N
N OH
N NaCl
+ 3 CH3OH +
5-(2-Methoxy-phenoxy) Methanol Sodium Chloride
-[2,2']bipyrimidinyl-4,6-diol 3X32.04=96.12 58.44
C15H12N4O4
312.28
Stage-3
Step-A
OH OCH3
O
N
N
N OH
N Toluene
+ POCl3 + 4 NaOH
Cl OCH3
O
N
N
N Cl
N Na3PO4 NaCl + 3H2O
+ +
Step-B
Cl OCH3
O O
O S
N NH2 OH
N H3C
N Cl
+ H3C HO
N CH3 + K2CO3 +
Toluene
H3C O
H3C S
NH OCH3
H3C O
O
N
N
N O
N HO
+ 2 KCl + CO2 + H2O
BOSENTAN
Flow Chart
Pyrimidine-2-carbonitrile
Ammonium chloride Stage-1 Methanol Rec
Methanol
Stage-1
2-(2-Methoxy-phenoxy)
malonic acid dimethyl ester Stage-2 Methanol Rec
Methanol
Stage-2
Phosphorous oxychloride Toluene Rec
Stage-3
Potassium carbonate Effluent water
Ethylene glycol
Toluene
BOSENTAN
BOSENTAN
Material Balance
2. DAPAGLIFLOZIN PROPANEDIOL
Process Description:
Stage-1
Stage-2
Stage-3
Stage-4
Stage- 3reacts with S (+)-1, 2-propanediol in presence of Methanol as a solvent media
to give Dapagliflozin Propanediol
DAPAGLIFLOZIN PROPANEDIOL
Route of Synthesis
Stage-1
O O O
HO
CH3
4
HO OH 4 H3C Si Cl N
HO + CH3 + CH3
MDC
O O
TMSO O
TMSO OTMS
4 N
TMSO HCl
+ CH3
3,4,5-Tris-trimethylsilanyloxy N-Methyl morpholine
-6-trimethylsilanyloxymethyl Hydrochloride
-tetrahydro-pyran-2-one C5H12ClNO
C18H42O6Si4
4X137.61=550.44
466.86
Stage-2
O O
Cl O CH3 TMSO
TMSO OTMS
Br
+ OTMS + 4 H2O + CH3OH
Toluene n-BuLi
Cl
O
HO
OCH3
HO OH
OH CH3
4 H 3C Si OH
O CH3
+ CH3 HBr + 1/2O2
+
2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6 Trimethyl-silane Hydrogen Oxygen gas
-hydroxymethyl-2-methoxy-tetrahydro 4X90.20=361.80 bromide 1/
2X32=16.0
pyran-3,4,5-triol 80.91
C22H27ClO7
438.90
Stage-3
Cl
O
HO
OCH3
HO OH
CH3
OH H3C
Si
O CH3
H H2O
+ CH3 +
2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6 Triethylsilane 18.00
-hydroxymethyl-2-methoxy-tetrahydro
C6H16Si
pyran-3,4,5-triol
C22H27ClO7 116.28
438.90
MDC
Cl
O
HO
HO OH
OH CH3
H3C
O CH3 Si
+ OH CH3OH
CH3 +
Dapagliflozin Tech
C21H25ClO6 Triethylsilnol Methanol
408.87 C6H16OSi 32.04
132.28
Stage-4
Cl
O
HO
HO OH
OH HO OH
O CH3
+ CH3 + H 2O
Dapagliflozin Tech S-(+) Propane-1,2-diol
18.00
C21H25ClO6 C3H8O2
408.87 76.09
Cyclohexane
Cl
O
HO
HO OH
OH HO OH
H 2O
O CH3
CH3
Dapagliflozin Propanediol
C24H35ClO9
502.98
DAPAGLIFLOZIN PROPANEDIOL
Flow Chart
Gluconolacotone
Trimethylsilane Chloride
Stage-1 MDC Rec
N-Methylmorpholine
MDC
Stage-1
4-Bromo-1-chloro-2-(4-ethoxy
benzyl) benzene Stage-2 Toluene Rec
N-BuLi
Toluene
Stage-2
Triethyl silane Stage-3 MDC Rec
MDC
Stage-3
Propylene glycol
Stage-4 Methanol Rec
Isopropylacetate
Methanol
DAPAGLIFLOZIN PROPANEDIOL
DAPAGLIFLOZIN PROPANEDIOL
Material Balance
3. PONATINIB
Process Description
Stage-1
Stage-2
PONATINIB
Route of Synthesis
Stage-1
CH3
N
O H3C
I
Cl H3C N CH3
F
H2N
F H3C + CH3 CH3
F +
4-(4-Methyl-piperazin-1-ylmethyl) 3-Iodo-4-methyl-benzoyl Ethyl-diisopropyl-amine
-3-trifluoromethyl-phenylamine chloride C8H19N
C14H19F3N3 C8H6ClIO
129.24
273.30 280.49
Ethyl acetate
CH3
H3C
O
I F H3C N CH3
N
H F Cl
F H
+ CH3 CH3
H3C
3-Iodo-4-methyl-N-[4-(4-methyl-piperazin Ethyl-diisopropyl-amine
-1-ylmethyl)-3-trifluoromethyl Hydrochloride
-phenyl]-benzamide
C8H20ClN
C21H23F3IN3O
165.70
517.33
Stage-2
CH3
N
N
O
N MDC
I F N
N
H F C
F +
H3C CH
3-Iodo-4-methyl-N-[4-(4-methyl-piperazin 3-Ethynyl-imidazo
-1-ylmethyl)-3-trifluoromethyl [1,2-b]pyridazine
-phenyl]-benzamide C8H5N3
C21H23F3IN3O 143.15
517.33
N CH3
N N N
C
N
C
H3C
F
NH
F
F
O
+ HI
PONATINIB
Flow Chart
4-(4-Methyl-piperazin-1
-yl methyl)-3-trifluoromethyl
phenyl amine Stage-1 Ethylacetate Rec
3-Iodo-4-methyl-benzoyl chloride
Ethyl-diisopropyl amine
Ethylacetate
Stage-1
3-Ethylnyl-imidazo Stage-2 MDC Rec
[1, 2-b] pyridazine
MDC
PONATINIB
PONATINIB
Material Balance
4. POSACONAZOLE
Process Description:
Stage-1
Stage-2
Stage-1 product reacts with Hydrogen in the presence of Palladium carbon as Catalyst
by using Acetone as solvent media to give Stage-2 as product.
Stage-3
Stage-2 product undergoes purification with IPA, MDC as solvent media to give
Posaconazole as product
POSACONAZOLE
Route of Synthesis:
Stage-1
F F
N
N N OTs
O
N N O O
HO N
+ N + NaOH
N
DMSO
O CH3
F F
N
O N N N
N O
O
N CH3
N
N
Benzylated Posaconazole
C44H48F2N8O4 O
ONa
790.90 S
O
+ H2O +
p-Toluene sulfonic
18.0
acid sodium salt
C7H7NaO3S
194.18
Stage-2
O CH3
F F
N
O N N N
N O
O
N CH3
N
N
+ H2
Benzylated Posaconazole
Hydrogen
C44H48F2N8O4 2.0
790.90
Acetone
O CH3
F F
N
O N N N
N OH
O
N CH3
N
N +
Toluene
Posaconazole (Crude)
C7H8
C37H42F2N8O4
92.14
700.78
Stage-3
O
F F CH3
N
O N N N
N OH
O
N CH3
N
N
Posaconazole (Crude)
C37H42F2N8O4
700.78
MDC
O
F F CH3
N
O N N N
N OH
O
N CH3
N
N
Posaconazole (Pure)
C37H42F2N8O4
700.78
POSACONAZOLE
Flow Chart:
4-Hydroxyphenyl-piperazinyl
triazolone
DMSO Stage-1 Ethyl acetate Rec
Tosyl sulfonyl
methyl ester
Ethyl acetate
Stage-1
Methanol
Stage-2 Acetone Rec
Hydrochloric acid (35%)
Sodium hydroxide
Acetone
Stage-2
MDC Stage-3 MDC Rec
Isoproponal Isoproponal Rec
POSACONAZOLE
POSACONAZOLE
Material Balance:
5. VIDAGLIPTIN
Process Description:
Stage-1
Amantadine Hydrochloride reacts with Sulfuric acid, Nitric acid and Sodium hydroxide in
the presence of MDC as solvent media to give Stage-1 as product.
Stage-2
VIDAGLIPTIN
Route of Synthesis:
Stage-1
Cl
MDC
NH2 H
+ H2SO4 + HNO3 + 4NaOH
HO
Na2SO4 + NaNO2 + NaCl + 4H2O
NH2 +
Stage-2
HO
N
NH2 Cl THF
+
+ K2CO3
O CN
3-Amino-adamantan-1-ol (S)-1-(2-Chloroacetyl)pyrolidine Potasisum
C10H17NO -2-carbonitrile carbonate
C7H9ClN2O
167.25 138.21
172.61
HO O CN
NH
N
+ KCl + KOH + CO2
VIDAGLIPTIN
Flow Chart:
Amantadine Hydrochloride
Conc. Nitric acid
Conc. Sulfuric acid Stage-1 MDC Rec
Sodium hydroxide
MDC
Stage-1
(S)-1-(2-Chlororacetyl
)pyrrolidine-2-carbonitrile Stage-2 THF Rec
Potassium carbonate
Potassium Iodide
THF
VIDAGLIPTIN
VIDAGLIPTIN
Material Balance:
S. No Purpose Effluent
In KLD
1 Process 6.92
2 Washings 1.00
3 Boiler Blow down 2.00
4 Cooling Towers Blow down 2.00
5 Scrubbing system 1.00
6 Domestic 0.70
Total 13.62
(iii) Need for the project and its importance to the Enclosed
country and or region
3. Project Description
(i) Type of project including interlinked and R& D and Pilot scale Manufacturing
interdependent projects, if any Of Bulk Drugs & Intermediates.
(viii) Availability of water its source, Energy/ power Bore well water.
Requirement and source should be given.
4. Site Analysis
5. Planning Brief
6. Proposed Infrastructure
(i) Industrial Area (Processing Area). --
(ii) Estimated project cost along with analysis in terms of 4.50 Crores
economic viability of the project.
(i) Financial and social benefits with special These types of industries will
emphasis on the benefit to the local people contribute in development of local
Including tribal population, if any, in the area. villagers because of employment to
the locals.
27. An action plan to control and monitor secondary fugitive emissions from all the Sources
28. Determination of atmospheric inversion level at the project site and assessment of ground
level concentration of pollutants from the stack emission based on Site-specific
meteorological features
29. Air quality modelling for proposed plant
30. Action plan for Zero Liquid Discharge of effluent should be included. Segregation of the
Wastewater should be based on the pollution load and high TDS effluent should be treated in
MEE
31. Ground water quality monitoring minimum at 6 locations should be carried out.
32. Geological features and Geo-hydrological status of the study area and ecological status
(Terrestrial and Aquatic)
33. The details of solid and hazardous wastes generation, storage, utilization and disposal
particularly related to the hazardous waste calorific value of hazardous waste and detailed
characteristic of the hazardous waste. Action plan for the disposal of fly ash generated from
boiler should be included
34. Precautions to be taken during storage and transportation of hazardous chemicals should
be clearly mentioned and incorporated
35. Membership for the disposal of liquid effluent in CETP or Zero Liquid discharge action
plan and solid/hazardous waste in TSDF
36. An action plan to develop green belt in 33 % area
37. Occupational health of the workers needs elaboration including evaluation of Noise, heat,
illumination, dust, any other chemicals, metals being suspected in Environment and going
into body of workers either through inhalation, ingestion or through skin absorption and steps
taken to avoid musculo-skeletal disorders (MSD), backache pain in minor and major joints,
fatigue etc. Occupational Hazards specific pre-placement and periodical monitoring should
be carried out
38. Socio-economic development activities should be in place
39. Note on compliance to the recommendations mentioned in the CREP guidelines
40. Detailed Environment management Plan (EMP) with specific reference to details of air
pollution control system, wastewater management, monitoring frequency, responsibility and
time bound implementation plan for mitigation measure should be provided
41. Any litigation pending against the project and/or any direction/order passed by any Court
of Law against the project, if so, details thereof
42. A tabular chart with index for point wise compliance of above TORs
PROJECT REPORT
OF
Syn-Finechem
Laboratories Pvt. Ltd.
OFFICE
# D-151, Phase – IIII D A, Jeedimetla,
Hyderabad – 500055 Andhra Pradesh, India.
Tel: 040-23095094Fex: 040-23194700
70
# Syn-Finechem Laboratories Pvt. Ltd.
CONTENTS
A. Glimpse
D. Product Description
E. Market Survey
F. Infrastructure facilities
G. Technical Know-How
I. Swot Analysis
71
# Syn-Finechem Laboratories Pvt. Ltd.
GLIMPSE
72
# Syn-Finechem Laboratories Pvt. Ltd.
COST OF PROJECT:
Particulars Amount
Rs in laks
Land 100.00
Building, Civil works& site development 100.00
Plant and Machinery 100.00
73
# Syn-Finechem Laboratories Pvt. Ltd.
Building and Civil Work:
The company has constructed the basic structures required for housing the machinery
& equipment, stores at a cost of Rs. 3.50 Crores Cost for civil works is around 1.00
Crores. The buildings are completed erecting the machinery & equipment. A detailed
statement of area-wise civil works completed by the Company as on date is prepared.
All the Plant and Machinery required for the proposed project would be procured
indigenously and the Cost for the equipment is around 450.00 Lakhs.
1 Production Block
250.00
2 QC & QA
50.00
3 Ware House
20.00
4 Utility Blocks
a) Service Block
30.00
b) Boiler Block
10.00
c) Power Generation& Main controls
10.00
d) HT Yard
10.00
5 Effluent Treatment Plant (ETP)
70.00
Total Plant & Machinery
450.00
74
# Syn-Finechem Laboratories Pvt. Ltd.
Implementation Schedule:
Activity Time frame for completion
Acquisition of land and Land Acquired
development
Construction of factory Constructed
buildings
Plant and Machinery. -
Process Equipment Installed and under working condition
-
Commercial Production August-2003
THE PROMOTERS
Dr. B. Saida Reddy, Doctorate in Chemistry, has work experience of more than
25years Bulk Drug industries.
Mrs. B. Chandra Kala, Post Graduate in Economics, has work experience of more than
10 years.
Mr. B. Kartheek Reddy, B. Tech in Electrical Engineering, has work experience of more
than 5 years.
Mr. B. Ashwik Reddy, B. Tech in Chemical Engineering from IIT, has experience in
Designing of Reactors, Condensers and Distillation Columns.
75
# Syn-Finechem Laboratories Pvt. Ltd.
PRODUCT DESCRIPTION
Intermediates which are the active ingredients with medicinal properties and are the
best raw materials for making Bulk Drugs and Formulations which are specific dosage
forms of a Bulk Drug or of a combination of different Bulk Drugs and the final form in
which the drugs are sold i.e. syrups, injections, tablets, and capsules.
The Company proposes to manufacture the following products and their
intermediates.
PROPOSED PRODUCTS
MARKET SURVEY
The field of Bulk Drugs and intermediates is broad-based. It covers all products and
preparations used in the production of pharmaceutical formulations. The bulk drugs
industry segment in India has been able to establish its presence in the international
markets and more than 60 percent of its produce is exported. This segment has
managed tremendous growth, with production of only Rs. 0.18 billion in 1960, rising to
Rs. 10.0 billion by 2005 and hence meeting 70 percent of the domestic requirement.
The segment is a net foreign exchange earner producing export quality drugs; with bulk
drugs export accounting for 60 percent of the total pharma industry exports. Exports of
bulk drugs are growing by 30 percent per year. But given the size of the world market,
supply from India is miniscule – India’s exports account for only 1.0 percent of the
worldwide demand. In terms of the inputs used in production of drugs the industry faces
low cost of inputs at competitive rates helped by the presence of a well developed
chemical industry.
76
# Syn-Finechem Laboratories Pvt. Ltd.
As the manufacture of most bulk drugs is neither capital intensive nor technology
intensive, process re-engineering encouraged the growth of production bases. There
are a large number of bulk drug manufacturers in India, including many small scale
industries. This has increased competition, leading to a drop in prices and consequently
lower margins. Most bulk drugs under the DPCO sell below the government
administered prices due to stiff competition and lower import tariffs.
As per IMS Retail Drug Monitor, sales through pharmacies in thirteen leading markets
for the year to August 2003 are $ 298.7 Billion. According to the IMS World Review, in
2004, global audited sales of pharmaceuticals rose 8% (at a constant dollar rate) to
reach US $ 400.6 Billion. IMS world Review tracks actual sales of approximately 90% of
all prescription drugs and certain over-the-counter (OTC) products in more than 70
countries. Using proprietor data projection methodologies to estimate total global
pharmaceuticals sales, which grew to US $ 430.3 Billion in 2005. Despite economic
challenges in the worlds leading markets and a lower-than-normal number of new
product introductions, the global pharmaceutical industry experienced good growth in
2005.
77
# Syn-Finechem Laboratories Pvt. Ltd.
Pharmaceuticals market over the next decade; Doubling of disposable incomes and
the increase in numbers of middle class households , significant expansion of medical
infrastructure, greater penetration of health insurance, a gradual shift in disease profile
and adoption of patented products, and finally population growth.
It ranks very high in the third world, in terms of technology, quality and range of
medicines manufactured. Playing a key role in promoting and sustaining development in
the vital field of medicines, the Indian Pharmaceutical Industry boasts of quality
producers and many units approved by regulatory authorities in USA and UK.
Internationally Companies associated with this sector have stimulated, assisted and
spearheaded this dynamic development in the past 50 years and helped to put India on
the pharmaceutical map of the world.
The Indian Pharmaceutical sector has more than 20,000 registered units. It has
expanded drastically in the last two decades. The leading 250 pharmaceutical
Companies control 70% of the market. The pharmaceutical industry in India meets
around 70% of the country’s demand for bulk drugs, drugs intermediates,
pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables. There
are about 250 large units and about 8000 small Scale Units, which form the core of the
pharmaceutical industry in India (including 5 Central Public Sector Units). These units
produce the complete range of pharmaceutical formulations, i.e. medicines ready for
consumption by patients and about 350 bulk drugs, i.e. chemicals having therapeutic
value and used for production of pharmaceutical formulations.
78
# Syn-Finechem Laboratories Pvt. Ltd.
The exports from the state stood at US $ 1.0 billion in 2004-05 registering an annual
growth of more than 20%. The sector accounts for about 20 % of the total exports from
state.
Most of the companies have set up their R&D facilities in the state, thus making the
state the pharmaceutical capital of the country.
Hyderabad has developed as a major production center for bulk drugs due to the
location if the many major Pharmaceutical Industries such as Dr. Reddy’s Laboratories,
Aurobindo Pharma, Neuland Laboratories, Siris, Hetaro Drugs, Divis Labs, Natco
Pharma Limited, Matrix Labs, Nicholas Piramal etc., besides a large number of medium
and small industries manufacturing bulk drugs of all kinds.
To name a few Ge, AstraZeneca, Biocon, Cipla, Strides Arcolab, Himalaya drugs,
Karnataka antibiotics and pharmaceuticals ltd, Hinkle and Micro labs.
In support of this growth in Hyderabad and Bangalore, many basic chemical units and
drug intermediate units have also come up to meet the input requirements of Bulk Drug
manufacturing Companies. Large numbers of these units are still dependent on supply
of basic chemicals mainly from Mumbai, Gujarat and other parts of the country involving
heavy expenditure on transport and transit risks.
So, considering the above factors, it is assured that setting up of basic drug
intermediate unit near Hyderabad will be of better prospect as we can meet the needs
of the Bulk Drug units located in and around Hyderabad. The products can be supplied
to the bulk consumers speedily and at lower prices reducing transport cost and time and
transit risks. The products can also be exported easily of proper marketing tie-ups are
made with the overseas bulk drug manufacturers in the due course as there is good
export potential for the basic drugs and intermediates.
79
# Syn-Finechem Laboratories Pvt. Ltd.
UTILITIES
a) Power
Requirement of power and its arrangements:
The company has 74 H.P. power connected and required 176 HP for the proposed
project from state electricity board. The company also having 1DG set of 63 8KVA and
to acquire 1 more DG set of 125 KVA as standby arrangement.
b) Water
Requirement of Water
The unit requires about 31.80 KLD of water per day for process and other uses. The
required amount of water can be obtained by Bore well water.
C) Boiler
The company proposes to install 2.0 MT/Hr coal fired boilers.
c) Man power:
The man power requirement of project is as under:
Particulars No. of Functional Area
employees
Key managerial staff 5 Finance, Marketing, Production, Quality
control, R&D, Logistics etc.
Administration 10 Office work
Skilled and semi 40 Production Process, Maintenance, stores,
skilled Safety & Un skilled workers
Total 55
Qualified and Skilled man power is available in and around Hyderabad on permanent
and temporary basis. We can also utilize services of experts on ad-hoc basis for
production of specialty products.
80
# Syn-Finechem Laboratories Pvt. Ltd.
The company is planning to have good team of employees in all areas. Looking in to
long term planning, company will take all the necessary steps to develop a good team of
work force. The company will provide all basic amenities to staff such as Medical
Health, children education, transport, canteen facility, transport, clothing, financial
assistance, family welfare etc.
The company will organize training classes for all the staff in the areas of Process up
gradation, Quality control, cost reduction techniques, safety etc.
81
# Syn-Finechem Laboratories Pvt. Ltd.
TECHINCAL KNOW-HOW
To supervise day to day production process, the company will appoint technically
qualified and experienced persons having relevant experience in the line of
manufacturing of Bulk drug intermediates.
The Unit will have well experienced, skilled and dedicated work force.
Selling and Marketing Arrangement:
The Company, by virtue of its well experienced directors in the field of Bulk drugs and
pharmaceuticals, has well established market connections. The company directors have
good relations with top executives of many reputed pharma companies and traders by
virtue of which fresh orders can be organized at any given time. Many recognized
companies assured their orders to the company and many more orders are expected
based on the completion of facility and regular production.
Our products and their intermediates are used in many organizations, and it is proposed
to enter into long term contract with these organizations. To name a few
82
# Syn-Finechem Laboratories Pvt. Ltd.
10 Micro labs-Bangalore
11 Auctus Pharma Limited
12 Hinkle Pharma
13 Cipla
14 Laurua Labs Ltd -.India
Also, the Company proposes to have its own market network by appointing experienced
marketing staff and dealers to sell the products.
The company also approached many prospective buyers who have assured to give their
requirement on conversion basis (Buy back arrangements) so that the company can
have both self products and conversion market also. This will enable the company to
have better control in plant operation, better market and financial flexibility.
SWOT Analysis
Strengths:
• The Promoters are technically qualified, well experienced and financially sound
besides possessing the required managerial competence and business skills to
make proposed project and successful and profitable venture.
• Procurement of raw material is very easy, since Hyderabad and Bangalore being
major pharma production center in India.
• Well Developed Industry with Strong Manufacturing Base and present industry
conditions are favorable.
• Access to pool highly trained scientists.
Opportunities:
• Drug Price Control Order puts unrealistic ceilings on product prices and
profitability and prevents pharmaceutical companies from generating investible
surplus.
• The new MRP based excise duty regime threatens the existence of many small
scale pharma units, especially in the states of Andhra Pradesh and Maharashtra
that were involved in contract manufacturing for the larger, established players.
These companies are now shifting their manufacturing from these states to
states like Himachal Pradesh, Uttaranchal that enjoy tax holidays.
Though the Company is promoted by first generation entrepreneurs, the Promoters are
technically qualified, well experienced and financially sound besides possessing the
required managerial competence and business skills to make proposed project a
successful and profitable venture. Further the Company has identified and proposes to
appoint professionals in key areas of Production, Research & Development, marketing,
logistics and Finance.
The company aims to keep abreast with the dynamic business scenario and will broad-
based its product mix. The Company, continuous R&D activities, will develop better
process technology, improved process yield, sourcing of raw material at competitive
price and development of new products/processes.
84
# Syn-Finechem Laboratories Pvt. Ltd.
3. The prices of Raw Material/solvent consumed by the Company are susceptible
to volatility. A majority of these raw materials are basic chemical, the demand for
which is not dependent on demand by pharmaceutical industry. The other
industries, which are generally much bigger consumer of such chemicals, tend to
determine market prices of such basic chemicals; such volatility may affect
company’s profitability.
The raw materials consumed are general chemicals and are available in India as well as
in many countries around the world at competitive prices. The company does not see
any problem in procuring the raw material/solvent at competitive prices.
All the major producers are having plans to go for expansion in the production facilities.
The other primary producers are having high fixed overheads and their market is
through dealers. But the Company is having established market connections
85